Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis
|First Received Date ICMJE||September 6, 2005|
|Last Updated Date||April 26, 2006|
|Start Date ICMJE||June 2000|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE
||Progressive renal function loss (= reduction in estimated Cr clearance by >20%) after 2 yrs follow-up, with an extended follow-up of 5 yrs|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT00150943 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis|
|Official Title ICMJE||The Benefit of STent Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR)|
Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipidlowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients.
Patients with an ARAS of ≥50% and renal failure (creatinine (Cr) clearance <80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance >20% compared to baseline. This trial will include 140 patients.
This is a randomized, multicenter trial of patients with an ostial ARAS and renal failure. Patients will be randomized to:
(i)medical treatment consisting of antihypertensive, lipid-lowering and antiplatelet therapy plus the advice to stop smoking; or (ii)medical treatment as outlined in (i) with additional stent placement.
Patients with an ostial ARAS, a Cr clearance of <80 mL/min/1.73m2 according to the Cockcroft and Gault formula and stable blood pressure (BP) control are enrolled in this trial. Ostial ARAS is defined as a luminal reduction of ≥50% of the renal artery within 1 cm of the aortic wall, in the presence of atherosclerotic changes of the aorta. Stenosis evaluation can be performed on CT-angiography, MR angiography or intra-arterial angiography.
Medical therapy: Irrespective of baseline serum cholesterol values, the patients will be treated with lipid-lowering therapy: 10 mg of atorvastatin and if this is well tolerated the dose will be doubled to the final dose of 20 mg. Any lipid-lowering medication currently used is discontinued and replaced by atorvastatin. Hypertension is treated with the following drugs: thiazide diuretic, calcium antagonist, beta-blocker and alpha-blocker. ACE-inhibitors/angiotensin-II-antagonists together with increasing loop diuretic doses, should be used only as a last resort antihypertensive treatment when other classes of antihypertensive agents have failed. The target BP is <140/90 mmHg. Patients will receive anti-platelet therapy, aspirin 75-100 mg/od. Considering that smoking is a major renal risk factor, smokers will be advised to stop.
Stent and medical therapy: Medical therapy is identical in the two treatment arms. In the stent group, patients will start with aspirin 75-100 mg/od the day before admission. The stent (Palmaz-Corinthian IQ/Palmaz Genesis, Johnson & Johnson Medical, NV/SA) will be placed during an in-patient admission according to a standardized protocol.
Randomisation will be done per participating centre and will be stratified for unilateral or bilateral abnormalities. An unilateral abnormality is defined as an unilateral ostial stenosis and on the other side a normal renal artery or a truncal stenosis (a truncal stenosis is nearly always easy to dilate by angioplasty). All other patients are considered to have bilateral abnormalities
Clinical follow-up is scheduled after 1, 3 and then every 3 months for the first 2 yrs and every 6 months until the 5 yr follow-up is completed. Economic data are assessed after 3 mths and every 3 mths for 2 yrs. Quality of life will be measured by standardized SF-36 and EQ-5D health questionnaires before, after 1 mth and every 6 mths for 2 yrs.
Indications for stent placement in the medically treated patients and re-angiography and balloon dilatation of the stent in the stented patients are: (i) a persistent >20% reduction of Cr clearance; (ii) therapy refractory hypertension (defined as an office BP >180/100 mmHg during three follow-up visits and subsequently a mean daily BP of >160/95 mmHg on 24 hr ambulant BP monitoring, while on the maximum dose of all classes of antihypertensives); (iii) pulmonary edema in the presence of bilateral renovascular disease and a normal or slightly impaired left ventricular function on echocardiography in combination with ACE-inhibitors/angiotensin-II antagonist intolerance defined as a fall of estimated Cr clearance by >20% and; (iv) malignant hypertension (defined as fundus grade III/IV).
Analysis of results: The difference in the proportion of patients with progressive renal dysfunction between both treatment arms will be assessed including 95% confidence intervals (95% CI). Mean change and difference in renal function change, including 95% CI will be reported. With multivariate logistic regression analysis not only will the effects of the two treatment strategies be evaluated, but also whether there are independent effects of age, smoking, proteinuria, bilateral or unilateral renal artery stenosis, BP and renal function at baseline.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 3|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Intervention ICMJE||Device: Renal artery stent|
|Study Arms||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||Not Provided|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Netherlands|
|Removed Location Countries|
|NCT Number ICMJE||NCT00150943|
|Other Study ID Numbers ICMJE||C99.1810-STAR, C99.1810|
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor ICMJE||UMC Utrecht|
|Collaborators ICMJE||Not Provided|
|Information Provided By||UMC Utrecht|
|Verification Date||April 2006|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP